Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Gemcitabine, and Radiotherapy in Pancreatic Cancer
NCT00225784Phase 2Completed
- Sponsor
- Dartmouth Health
- Start
- Feb 2005
- Primary completion
- Feb 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cetuximab in pancreatic adenocarcinoma (PDAC), sponsored by Dartmouth Health. Started Feb 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00225784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225784.